Phase 1 Myasthenia Gravis Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled3 locationsNCT07304154
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1Phase 2
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled10 locationsNCT06704269
Recruiting
Phase 1
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Myasthenia GravisMuscle WeaknessAutoimmune Diseases+4 more
Arcellx, Inc.30 enrolled13 locationsNCT06626919
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Myasthenia Gravis
ImmunAbs Inc.96 enrolled25 locationsNCT07250750
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Not Yet Recruiting
Phase 1
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants with Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled2 locationsACTRN12625001346460
Recruiting
Phase 1
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Generalized Myasthenia Gravis
Candid Therapeutics44 enrolled1 locationNCT07215650
Recruiting
Phase 1
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Myasthenia Gravis
Ting Chang, MD9 enrolled1 locationNCT06371040
Recruiting
Phase 1
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
Myasthenia Gravis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.50 enrolled1 locationNCT06688435
Recruiting
Phase 1
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Myasthenia GravisSystemic Lupus Erythematosus (SLE)Multiple Sclerosis (MS)+3 more
RenJi Hospital30 enrolled1 locationNCT06249438
Recruiting
Phase 1Phase 2
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Myasthenia GravisNMO Spectrum DisorderChronic Inflammatory Demyelinating Polyradiculoneuropathy+1 more
Tianjin Medical University General Hospital27 enrolled1 locationNCT07022197
Recruiting
Phase 1
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Myasthenia GravisMultiple Sclerosis (MS)Neuromyelitis Optica Spectrum Disease (NMOSD)+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology37 enrolled3 locationsNCT06869278
Recruiting
Phase 1Phase 2
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more
COUR Pharmaceutical Development Company, Inc.54 enrolled17 locationsNCT06106672
Recruiting
Phase 1
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis
Myasthenia Gravis
Zhejiang University9 enrolled1 locationNCT05828225